Extraordinary General Meeting held in Nordic Nanovector ASA

Reference is made to the notice of Extraordinary General Meeting distributed to the shareholders of Nordic Nanovector ASA (the “Company”) on 4 November 2014.
The proposals set out in the notice of the Extraordinary General Meeting have today been resolved. This included, among other things, the conversion of the Company into a public limited company, Board and Nomination Committee elections and remuneration, instructions for the Nomination Committee and amendments to the Company’s articles of association.
Pursuant to the resolutions resolved in the General Meeting, the Company’s Board of Director is composed of the following persons:
• Ludvik Sandnes (Chairman)
• Roy H. Larsen
• Alexandra Morris
• Hilde Steineger
• Per Samuelsson

The General Meeting also resolved to increase the share capital by up to NOK 3,450 by the issuance of maximum 17,259 new shares in a share capital increase towards the Board Members who choose to receive remuneration in the form of shares to be subscribed to for their nominal value and which, based on a market price of NOK 30, have a value that correspond to the remuneration of the Board member resolved by the General Meeting.
The minutes of the Extraordinary General meeting is attached to this press release.


Luigi Costa

Chief Executive Officer

Cell: (+41) 79 12 48 601

E-mail: lcosta@nordicnanovector.com

Tone Kvåle

Chief Financial Officer

Cell: (+47) 91 51 95 76

E-mail: tkvale@nordicnanovector.com

About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).


About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com